semaglutide biochemistry The Discovery and Development of Liraglutide and Two-year effects of semaglutide in

Does it have therapeutic effects

For type 2 diabetes, most patients stop at 0.51.0 mg

The capabilities are genuinely differentiated: a) ADC: Filed 3 payload DMFs in FY26, completed first cGMP bioconjugation campaign at NJ Bio (US facility), expanding with $10 Mn capex for Phase 2/validation readiness, traction in exatecan-linked platforms b) Oligonucleotide : cGMP building block facility under validation through the Sapala platform, follow-on purchase orders received c) Small Molecule CDMO: 140+ active projects, 70%+ from commercial products, 90%+ reload conversion rate d) Phase 3 pipeline: 10 programs including 1 under priority review and 1 awaiting clinical data readout However, FY26 was operationally challenging

Before we talk about how Johnson is lowering his biological age, we first need to understand the test he used to measure it The Horvath Clock Test